8-K: Cassava Sciences Unveils Promising Preclinical Data for Simufilam in TSC-Related Epilepsy, Targets H1 2026 Clinical Trials

Cassava Sciences announced compelling preclinical data demonstrating simufilam's efficacy in reducing seizures in a mouse model of Tuberous Sclerosis Complex (TSC)-related epilepsy, supported by a favorable human safety profile from prior Phase 3 Alzheimer's studies, with plans to initiate human clinical trials in the first half of 2026.

Summary

• Cassava Sciences presented preclinical data for simufilam at the TSC International Research Conference (TSC 2025) held from June 26-28, 2025, in Bethesda, MD.
• Preclinical studies showed that treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures.
• Simufilam significantly reduced seizure frequency (p<0.0001) and led to significantly more mice achieving seizure freedom (11 out of 32 simufilam-treated mice versus 3 out of 29 vehicle-treated mice, p=0.0343).
• Human safety data from two Phase 3 studies of simufilam in 1,929 patients with mild-to-moderate Alzheimer's disease demonstrated a favorable safety profile, with non-serious adverse events typically mild and not considered simufilam-related, and no serious adverse events assessed as study-drug related.
• The company plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy.
• Tuberous Sclerosis Complex (TSC) is a rare genetic disorder affecting an estimated 50,000 people in the United States and over one million worldwide, with 80% to 90% of patients experiencing lifelong epilepsy, and nearly two-thirds not responding to current antiepileptic drugs.

Sentiment

Score: 8

Explanation: The announcement presents strong positive preclinical efficacy data for a new, high-unmet-need indication (TSC-related epilepsy) combined with a favorable human safety profile from large Phase 3 studies. This significantly de-risks the initial steps for the new program and expands the company's pipeline, indicating strong potential for future value creation, despite the early stage of the new indication.

Positives

• Simufilam significantly reduced seizure frequency by 60% in a preclinical mouse model of focal onset seizures, indicating strong therapeutic potential.
• A statistically significant increase in seizure freedom was observed in simufilam-treated mice (11/32) compared to vehicle-treated mice (3/29), reinforcing efficacy.
• Favorable human safety data from two Phase 3 Alzheimer's disease studies involving 1,929 patients provides a robust safety profile for simufilam, with no study-drug related serious adverse events reported.
• Chronic oral toxicology studies showed no adverse effects at high doses (up to 50 mg/kg/day in rats and 1250 mg/kg/day in mice), supporting safety for future human trials.
• The company's plan to initiate human clinical studies for TSC-related epilepsy in H1 2026 demonstrates pipeline expansion into a high-unmet-need rare disease area.

Risks

• The ability to advance preclinical studies related to TSC-related epilepsy and other potential indications is uncertain.
• The ability to successfully carry out the company's obligations under the Yale License Agreement is a factor.
• Risks inherent in drug discovery and development, which is a long, complex, and costly process with a high degree of risk.
• Clinical results from earlier-stage clinical trials or preclinical studies may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval.
• Investment in publicly traded securities carries the risk of total loss of the money invested.

Future Outlook

Cassava Sciences plans to initiate human clinical studies in the first half of 2026 to evaluate simufilam as a treatment for Tuberous Sclerosis Complex (TSC)-related epilepsy. Additional preclinical studies are underway with the TSC Alliance preclinical consortium and other collaborators to further confirm these promising findings and explore simufilam's mechanism of action and its potential to treat TSC-related epilepsy.

Management Comments

• "My research and collaboration with the TSC Alliance demonstrate our commitment to address the high unmet need in people with TSC-related epilepsy. We are excited to share this research with the TSC community, including the preclinical data showing that simufilam significantly reduced seizure frequency. Additional pre-clinical studies are underway to further confirm these promising findings." Anglique Bordey, PhD, Senior Vice President, Neuroscience of Cassava.
• "The data we presented at TSC 2025 mark the Company’s first presentation of simufilam’s positive results in a preclinical model. These compelling preclinical data build on favorable safety findings from prior human clinical studies and support our plan to begin our first clinical study in TSC-related epilepsy in the first half of 2026." Rick Barry, President and Chief Executive Officer of Cassava.

Industry Context

This announcement positions Cassava Sciences to potentially enter the rare disease market for Tuberous Sclerosis Complex (TSC)-related epilepsy, a condition characterized by significant unmet medical need where current treatments are often ineffective or associated with serious adverse events. By diversifying its pipeline beyond Alzheimer's disease, Cassava is targeting a specific genetic disorder (mTOR pathway mutations) with a novel mechanism of action (modulating filamin A). This strategic move into a rare disease indication could offer a more streamlined regulatory pathway and potentially higher market exclusivity and pricing power if successful, contrasting with the highly competitive and challenging landscape of Alzheimer's drug development.

Comparison to Industry Standards

• Current treatments for TSC-related epilepsy, including antiepileptic drugs, mTOR analogs, and surgery, are noted as not fully effective, associated with serious adverse events, and/or invasive, highlighting a significant unmet medical need that simufilam aims to address.
• The preclinical data showing a 60% reduction in seizure frequency in a mouse model represents a strong initial efficacy signal, particularly relevant given the high non-response rate to existing therapies in TSC patients.
• The favorable safety profile observed in 1,929 patients across two Phase 3 Alzheimer's studies provides a robust and extensive human safety dataset, which is a significant advantage for a new indication and surpasses the typical safety data available at the preclinical stage for a novel therapy.
• While specific comparable companies or projects for simufilam in TSC are not detailed, the novel mechanism of action targeting filamin A offers a differentiated approach compared to existing mTOR inhibitors like everolimus, which are associated with their own side effect profiles.

Stakeholder Impact

• Shareholders: Positive impact due to pipeline expansion, promising preclinical data, and favorable safety profile, potentially increasing future value and diversifying risk beyond Alzheimer's.
• Patients (TSC-related epilepsy): Potential for a new, effective treatment option for a severe condition with high unmet need, offering hope for improved quality of life.
• Employees: Positive impact from progress in drug development and potential for new clinical programs.

Next Steps

• Conduct additional preclinical studies with the TSC Alliance preclinical consortium and other collaborators to further confirm findings and explore simufilam's mechanism of action.
• Initiate human clinical studies in H1 2026 to evaluate simufilam as a treatment for TSC-related epilepsy.

Key Dates

Recommendation

Keywords

Cassava Sciences, Simufilam, Tuberous Sclerosis Complex, TSC-related epilepsy, CNS disorders, preclinical data, clinical safety, Phase 3 studies, Alzheimer's disease, biotechnology, drug development, rare disease, seizure reduction, filamin A, mTOR pathway